Patients and Physicians Express Desire to Switch to Transdermal Drug Delivery, Finds Frost & Sullivan

Patients and Physicians Express Desire to Switch to Transdermal Drug Delivery, Finds Frost & Sullivan

- The growing challenge of medication adherence has significant health and financial implications

MOUNTAIN VIEW, Calif., July 11, 2013 /PRNewswire/ -- The $82 billion U.S. drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening Food and Drug Administration (FDA) regulations, and emerging drug delivery systems continuing to provide momentum. Among the 15 drug delivery systems surveyed by Frost & Sullivan, physicians prefer topical delivery, either as a transdermal patch or topical gel/cream, and expressed willingness to switch their current mode of therapy to one available in these forms.

A new end-user survey of more than 220 physicians and 650 patients by Frost & Sullivan, the Drug Delivery Technology: End-User Preferences, Utilization and Perceptions analysis (

http://www.lifesciences.frost.com( http://www.frost.com/prod/servlet/svcg.pag/HCLS )), finds that regardless of disease area, physicians select drug delivery methods that drive consistent patient compliance and effective outcomes. The survey traces usage patterns, analyzes preferences and opportunities among physicians and patients, and assesses their willingness to switch therapies based on the drug delivery method.

DRUG DELIVERY METHODS AND DISEASE TYPES COVERED

Delivery Method Disease Type

Oral drug delivery Type 1 diabetes

Nasal drug delivery Type 2 diabetes

Transdermal drug delivery Obesity

Topical drug delivery Deep vein thrombosis

Subcutaneous injection Arterial thrombosis

(autoinjector)

Subcutaneous injection Atrial fibrillation/arrhythmia

(prefilled syringe)

Intramuscular injection Ischemic heart disease

(autoinjector)

Intramuscular injection Migraines

(prefilled syringe)

Intradermal injection Multiple Sclerosis

Intravenous injection ADHD

Intravenous infusion Schizophrenia

Implantable infusion pump Alzheimer's disease

External infusion pump Depression

Implant Ulcerative colitis

Rectal drug delivery Crohn's disease

Psoriasis

Rheumatoid arthritis

For more information on this research, please email Britni Myers, Corporate Communications, at [email protected], with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

The route of administration and drug delivery technology has a huge bearing on the adoption of, and compliance with, new as well as existing drugs. Among the surveyed physicians, only a quarter were considered early adopters of new drug delivery forms. Accordingly, manufacturers must listen to actual selection criteria and level of satisfaction data collected from end-users to find commercial success among medical practitioners.

"All things considered, physicians usually lean toward the treatment they feel will be most acceptable to their patients in order to ensure good compliance," said Frost & Sullivan Vice President of Global Research Monali Patel Shastry.

These indicators are highly relevant in the current market scenario, wherein medication adherence is a growing concern, with momentous medical and economic consequences.

"When selecting the optimal drug delivery method, reimbursement incentives for improving adherence and impact on formulary decisions are proven to be important factors," noted Frost & Sullivan Life Sciences Senior Industry Analyst Deborah Toscano. "Drug development pipelines are full of innovative drugs and biologics, and differentiation is increasingly important in this crowded market to gain and maintain market share."

It is important to note the drivers of satisfaction and selection are not always the same across diseases and methods. For example, the several novel oral therapies for multiple sclerosis recently introduced offer significant advantages over the standard of care injectable therapies. However, more than 55 percent of physicians treating multiple sclerosis are likely to switch from the currently prescribed branded drug if the drug were available in a transdermal patch form, while 54 percent of the physicians treating migraines would prefer to switch to a drug using nasal administration.

This is in line with the 58 percent of multiple sclerosis patients willing to use a transdermal patch, and 50 percent of migraine patients willing to use a nasally administered drug. Further, 57 percent of physicians treating type 2 diabetes are most willing to switch from oral or injectable drugs to a topical treatment.

The Drug Delivery Technology: End-User Preferences, Utilization and Perceptions analysis is generated by Frost & Sullivan's global Life Sciences practice. Related research includes: Analysis of the Global Type 2 Diabetes Therapeutics Market, United States Market for Rheumatoid Arthritis Pharmacotherapeutics, and Strategic Analysis of Anti-Obesity Prescription Drug Development. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter( http://bit.ly/VykvA3 ), Facebook( http://on.fb.me/RCq1TX ), SlideShare( http://slidesha.re/URHckb ) and LinkedIn( http://linkd.in/Wphssa ), for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

-- The Integrated Value Proposition provides support to our

clients throughout all phases of their journey to

visionary innovation including: research, analysis,

strategy, vision, innovation and implementation.

-- The Partnership Infrastructure is entirely unique as it

constructs the foundation upon which visionary innovation

becomes possible. This includes our 360 degree research,

comprehensive industry coverage, career best practices

as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=Contact )

Join Us: Join our community( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=Join )

Subscribe: Newsletter on "the next big thing"( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=PRFooter )

Register: Gain access to visionary innovation( http://www.frost.com/prod/servlet/register-form.pag?refpage=http%3A//www.frost.com/prod/servlet/frost-home.pag&SRC=Register )

Drug Delivery Technology: End-User Preferences, Utilization and Perceptions

Contact:

Britni Myers

Corporate Communications -- North America

P: +1.210.477.8481

F: +1.210.348.1003

E: [email protected]

Twitter: @Frost_Sullivan( https://twitter.com/frost_sullivan )

Facebook: Frost & Sullivan( https://www.facebook.com/FrostandSullivan )

http://www.frost.com

SOURCE Frost & Sullivan

 

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.